Gabriel Brooks

📢 Our latest study by Dr. Angriman et al., "Preexisting Diabetes Mellitus and All-Cause Mortality in Adult Patients With Sepsis: A Population-Based Cohort Study," contains some surprising results, shedding light on the impact of preexisting diabetes on sepsis outcomes. 🧵 Here are the key findings: 🔍 In a population-based cohort study spanning 2008 to 2019, we found that adult patients with sepsis and preexisting diabetes had a lower risk of all-cause mortality at 90 days compared to those without diabetes. 💪 Despite facing a higher burden of comorbidities and frailty at baseline, patients with sepsis and preexisting diabetes had comparable lengths of hospital stay, incidence of septic shock, ICU admission, and severity of illness as measured by the multiple organ dysfunction score. 🩺 However, preexisting diabetes was associated with a significantly increased risk of new renal replacement therapy, highlighting the importance of close monitoring for renal complications in sepsis patients with diabetes. 💊 Notably, our study suggests that prior use of metformin, a common medication for diabetes, may play a role in reducing all-cause mortality at 90 days following sepsis. 🔬 These findings underscore the complex interactions between preexisting diabetes and sepsis outcomes, emphasizing the need for further research to understand underlying mechanisms and identify potential mitigation strategies. 📖 Read the full article here: https://lnkd.in/dyqbXUrR

3

Immunogenic cell death-based cancer vaccines promising prospect in cancer - Maryam Diba Tehran University of Medical Sciences https://lnkd.in/ge2rjrnB #oncodaily #oncology #cancer #cancervaccines #immunotherapy #immunogeniccelldeath #ICD #DAMPs #neoantigens #personalizedmedicine #chemotherapy #radiotherapy #photodynamictherapy #oncolyticviruses #antitumorimmunity #immunogenicity #antigenpresentation #resistance #apoptosis #necroptosis #ferroptosis #pyroptosis

47

4 Comments

Numerous studies conducted by Dana-Farber researchers show promising results for patients with endometrial, lung, breast, prostate, and colorectal cancers. The results of these studies, along with dozens of others led by Dana-Farber faculty, were presented at this year’s American Association for Cancer Research (AACR) Annual Meeting last month in California.   Notable research from Dana-Farber researchers included: Novel ADC and Immunotherapy Combo Shows Promise in Endometrial Cancer Subtype  Rebecca Porter, MD, PhD, a medical oncologist in the Gynecological Oncology Program of the Susan F. Smith Center for Women’s Cancers, presented results of a small, investigator-initiated phase 2 study of a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor. Blood Test May Identify Patients with Non-Small Cell Lung Cancer Subtype Who Can Benefit from Combination Therapy  Pasi Jänne, MD, PhD, senior vice president for Translational Medicine, presented an update to his practice-changing FLAURA2 clinical trial published last year, revealing that patients with non-small cell lung cancer (NSCLC) marked by a mutation in the EGFR gene fared significantly better when treated with the drug osimertinib plus platinum-based chemotherapy than with osimertinib alone. Exercise Program Can Improve Heart Function in Cancer Survivors  Cami Christopher, MPH, a research scientist in the Department of Medical Oncology, Population Sciences, presented findings suggesting that a moderate to vigorous aerobic and resistance exercise program can improve a key aspect of heart function in survivors of breast, prostate, and colorectal cancer. Study Provides First Large-Scale Look at Genetic Architecture of Prostate Cancer in Sub-Saharan Africa  Timothy Rebbeck, PhD, the Vincent L. Gregory Professor of Cancer Prevention, led the first large-scale genomic analysis of prostate cancer in sub-Saharan Africa which revealed that the genetic architecture of the disease – its basic underpinnings in abnormalities in DNA – is unique to Africa and varies across the continent. In addition, the AACR recognized Rebbeck, Christopher D.M. Fletcher, MD, FRCPath, and Gordon J. Freeman, PhD, with 2024 Scientific Achievement Awards during the Annual Meeting.  More: https://lnkd.in/etk8fwUp

58

1 Comment

👀 #ICYMI: At #AUA24, we talked with Yaw A. Nyame, MD, MS, MBA, about the “high-risk” population in #ProstateCancer as well as how different natural history affects screening results and implications for early detection. 📺 Watch Now:

13

Brace yourselves for the next-generation in clear aligners: NiTime™ Clear Aligners!  ✔ The only FDA-cleared aligners for shorter-wear time*  ✔ 9 to 12 hours wear time*  ✔ Compliance-friendly  ✔ More predictable and fewer refinements* NiTime Clear Aligners are powered by patented HyperElastic™ polymer with AirShell™ technology, defying the ordinary and outshining the leading aligners.  Visit the OrthoFX booth #1437 May 3-6 for a chance to win prizes and receive exclusive promotions. Come witness the future of clear aligners! #AAO #OrthoFX #ClearAligners #NiTime #HyperElastic #AirShell  *Data on file

48

2 Comments

nRichDX's Mayer Saidian, Ph.D. presented a poster titled, "Exploring Liquid Biopsy for the Detection of Bladder Cancer: Unraveling RNA Fusions" at the American Association for Cancer Research (AACR) Special Conference, "Bladder Cancer: Transforming the Field." in Charlotte, NC. The Conference concludes today and a pdf of the poster will be available shortly. Please email: info@nrichdx.com to request a copy. #liquidbiopsy #SamplePrepMatters #oncologyresearch #cancerresearch #bladdercancer

26

Cancer Precision Medicine Commons (https://lnkd.in/e7huMPyK) is presenting a webinar for patient advocacy groups and medical professionals on, "Best Practice Recommendations for development of patient education resources about Biomarker Testing and Genetic Testing for Inherited Cancer Risk" on May 22 at 2PM ET. Commons members will review resources and provide action and suggestions for utilizing them to support your efforts to educate patients about these important precision medicine tools. Register here: https://lnkd.in/erUc_3Hm #biomarkertesting #genetictesting #cancerrisk

8

1 Comment

🗣️ In a new Peer Exchange episode, #neurology experts provide an overview of emerging treatments in #MG, highlighting biomarkers and new routes of administration. 📺 https://lnkd.in/euKb3Du6

10

Patients with inoperable limited-stage small cell lung cancer (LS-SCLC) are treated with chemoradiation, but prognosis is limited. In a trial with 730 such patients who had not experienced progression after chemoradiation, the checkpoint inhibitor durvalumab improved median overall survival compared with placebo (56 versus 33 months), without added toxicity. For patients with LS-SCLC who have not experienced progression after concurrent chemoradiation, we now recommend durvalumab consolidation. Find out What's New in #oncology: https://ow.ly/8nPV50SvxOa #ClinicalUpdates #meded

8

1 Comment

Excited and honored to announce the publication of our multimedia article in the Annals of Surgical Oncology - Andrei Nikiforchin Ekaterina Baron, MD, Dr. Jessica A. Wernberg, and Dr. Rohit Sharma Sergei Iugai, Vladislav Kovalik, Vadim Gushchin, Armando Sardi, MD, FACS https://lnkd.in/gvh4t77U #oncodaily #oncology #cancer #surgicaloncology #surgery #roboticsurgery #paraganglioma #medicalvideo #perioperativemanagement #medicalresearch #multimediaarticle

16

CANCER RESEARCH - A conversation with Dr. Satish Gopal - Director of the Center for Global Health (CGH) at the National Cancer Institute (NCI)  at the #GlobalHealthCatalystSummit #cancerresearchblindspots #cancermoonshot2 #cancermoonshot

6

Nasopharyngeal Cancer: What patients should know about American Association for Cancer Research Cancer Research UK (CRUK) American Society of Clinical Oncology (ASCO) National Cancer Institute (NCI) UC San Diego Health University of California, San Francisco American Cancer Society https://lnkd.in/gYpTCijU #Cancer #PatientEducation #HeadAndNeckCancer #NasopharyngealCancer #OncoDaily #Oncology

14

Revolutionizing Cancer Research: The Power of Data Analysis with John Methot, FAMIA 🔬✨ Dana-Farber Cancer Institute mission is to cure cancer or make it a manageable and survivable disease. This mission is driven by comprehensive research, requiring the richest data sets on patient diagnosis, treatment, and outcomes. 📊🧬 Providing complete and detailed data enables comparative effectiveness of treatments, discovery of new biomarkers, and innovative prognosis methods. This critical information paves the way for inventing new treatments and improving patient care. 🌟💡 💡 Click the link in our bio for more stories on wellness! #TransformWellnessTogether #AIWellness #healthcare #healthandwellness #CancerResearch #DataAnalysis #InnovativeCare #DanaFarber

2

Hospital HCPs: Stay current on the latest NACI RSV immunoprophylaxis guidance for infants, including the recommended use of nirsevimab and RSVpref - plus discover how a hospital order set can support implementation of the new RSV immunoprophylaxis in your clinical practice.  Register today: https://ow.ly/2tw350RjU9t #RSVPrevention #MedEd #RSV #InfantHealth #RSV #RSVPrevention #InfantHealthcare #HealthcareWebinar #MedEd #RSVImmunoprophylaxis

2